詹勝傑副主任

詹勝傑醫師　
醫師代號 : 47022
學       歷 :  慈濟大學醫學系畢業

專 長(Areas of expertise)

  • 正子影像檢查(PET/CT)
  • 正子暨磁共振影像檢查(PET/MRI)
  • 核素治療(Radionuclide therapy)
  • 一般核醫影像檢查(General nuclear medicine)

現 職(Present)

  • 花蓮慈濟醫院核子醫學科副主任
  • 教育部部定副教授
  • 中華民國核醫學會理事
  • 慈濟大學醫學系副教授
  • 慈濟大學醫學系核子醫學科主任

經 歷 (Employment record)

  • 林口長庚醫院核子醫學科科主任
  • 基隆長庚醫院核子醫學科科主任
  • 嘉義長庚醫院核子醫學科科主任
  • 林口長庚醫院核子醫學科主治醫師

專科證書(Board certification)

  • 核子醫學科專科醫師證書(Nuclear medicine)

專科學會(Professional affiliation)

  • 中華民國核醫學學會(Society of Nuclear Medicine – Taiwan)
  • 台灣醫學會(Formosan Medical Association)

個人網站(Website)

https://www.researchgate.net/profile/Sheng-Chieh-Chan

近年研究計畫(Recent research grant)

  •      科技部研究案（Supported by Ministry of Science and Technology, Taiwan）
    • NSC 107-2314-B-182A-064; NSC 108-2314-B-182A-021; NSC 109-2314-B-303-009
    • NSC 110-2314-B-303-014

期刊論文(Journal publication)

  1. Predicting the risk of interval distant metastases in patients with esophageal squamous cell carcinoma undergoing chemoradiotherapy. J Formos Med Assoc. 2021. doi:10.1016/j.jfma.2021.06.002. (SCI A)
  2. Combing MRI Perfusion and 18F-FDG PET/CT Metabolic Biomarkers Helps Predict Survival in Advanced Nasopharyngeal Carcinoma: A Prospective Multimodal Imaging Study. 2021; 28;13:1550. doi: 10.3390/cancers13071550. (First author, IF=6.639)
  3. Prognostic Value of Baseline Radiomic Features of 18F-FDG PET in Patients with Diffuse Large B-Cell Lymphoma. Diagnostics (Basel). 2020;11:36. doi:10.3390/diagnostics11010036. (SCI A)
  4. Incorporating radiomic feature of pretreatment 18F-FDG PET improves survival stratification in patients with EGFR-mutated lung adenocarcinoma. PLoS One. 2020; 28;15:e0244502. doi: 10.1371/journal.pone.0244502. (Corresponding author, IF=3.24)
  5. Preoperative F-18 fluorocholine PET/CT for the detection of hyperfunctioning parathyroid glands in patients with secondary or tertiary hyperparathyroidism: comparison with Tc-99m sestamibi scan and neck ultrasound. Ann Nucl Med. 2020;34:527-537. doi: 10.1007/s12149-020-01479-2. (Corresponding author, IF=2.668)
  6. Multiparametric PET/MRI in nasopharyngeal carcinoma: correlations between MRI functional parameters and 18F-FDG PET imaging biomarkers and their predictive value for treatment failure. Tzu Chi Med J. 2020;33:61-69. doi: 10.4103/tcmj.tcmj_4_20. (First author)
  7. Pretreatment 18F-FDG PET/CT texture parameters provide complementary information to Epstein-Barr virus DNA titers in patients with metastatic nasopharyngeal carcinoma. Oral Oncol. 2020;104:104628. doi:10.1016/j.oraloncology.2020.104628. (SCI A)
  8. Prognostic Value of Lymph Node-To-Primary Tumor Standardized Uptake Value Ratio in Esophageal Squamous Cell Carcinoma Treated With Definitive Chemoradiotherapy. Cancers (Basel) . 2020;12:607. doi: 10.3390/cancers12030607. (SCI A)
  9. Radiation safety assessment of caregivers of thyroid cancer patients treated with 131I in Taiwan. Radiation Physics and Chemistry. 2020;172:108781. DOI: 10.1016/j.radphyschem. 2020.108781.
  10. Comparison of 18F-FDG PET/MRI, MRI, and 18F-FDG PET/CT for the detection of synchronous cancers and distant metastases in patients with oropharyngeal and hypopharyngeal squamous cell carcinoma. Eur J Nucl Med Mol Imaging. 2020;47:94-104. (Co-first author, IF=9.236)
  11. Baseline circulating stem-like cells predict survival in patients with metastatic breast cancer. BMC Cancer. 2019;19:1167. (SCI A)
  12. Textural features on 18F-FDG PET/CT and dynamic contrast-enhanced MR imaging for predicting treatment response and survival of patients with hypopharyngeal carcinoma. Medicine (Baltimore). 2019;98:e16608. (Co-first author, IF=1.889)
  13. Combining the radiomic features and traditional parameters of 18F-FDG PET with clinical profiles to improve prognostic stratification in patients with esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy and surgery. Ann Nucl Med. 2019;33:657-670. (Corresponding author, IF=2.668)
  14. Value of early evaluation of treatment response using 18F-FDG PET/CT parameters and the Epstein-Barr virus DNA load for prediction of outcome in patients with primary nasopharyngeal carcinoma. Eur J Nucl Med Mol Imaging. 2019;46:650-660. (Corresponding author, IF=9.236)
  15. Clinical utility of simultaneous whole-body 18F-FDG PET/MRI as a single-step imaging modality in the staging of primary nasopharyngeal carcinoma. Eur J Nucl Med Mol Imaging. 2018;45:1297-1308. (First author, IF=9.236)
  16. Predictive value of 1H MR spectroscopy and 18F-FDG PET/CT for local control of advanced oropharyngeal and hypopharyngeal squamous cell carcinoma receiving chemoradiotherapy: a prospective study. Oncotarget. 2017;14;8:115513-115525.
  17. Correlation between overall survival and differential plasma and tissue tumor marker expression in nasopharyngeal carcinoma patients with different sites of organ metastasis. Oncotarget. 2016;7:53217-53229.
  18. Higher body weight and distant metastasis are associated with higher radiation exposure to the household environment from patients with thyroid cancer after radioactive iodine therapy. Medicine (Baltimore). 2017;96:e7942. (SCI A)
  19. Multiparametric imaging using 18F-FDG PET/CT heterogeneity parameters and functional MRI techniques: prognostic significance in patients with primary advanced oropharyngeal or hypopharyngeal squamous cell carcinoma treated with chemoradiotherapy. Oncotarget. 2017;8:62606-62621. (First author)
  20. Tumor heterogeneity measured on F-18 fluorodeoxyglucose positron emission  tomography/computed tomography combined with plasma Epstein-Barr Virus load predicts prognosis in patients with primary nasopharyngeal carcinoma. Laryngoscope. 2017;127:E22-E28. (First author, IF=3.325)
  21. Efficacy of vancomycin-releasing biodegradable poly(lactide-co-glycolide) antibiotics beads for treatment of experimental bone infection due to Staphylococcus aureus. J Orthop Surg Res. 2016;11:52. (SCI A)
  22. Dynamic contrast-enhanced MRI, diffusion-weighted MRI and 18F-FDG PET/CT for the prediction of survival in oropharyngeal or hypopharyngeal squamous cell carcinoma treated with chemoradiation. Eur Radiol. 2016; 26:4162-4172. (SCI A) 
  23. Pretreatment Dynamic Contrast-Enhanced MRI Improves Prediction of Early Distant Metastases in Patients With Nasopharyngeal Carcinoma. Medicine (Baltimore). 2016;95:e2567. doi: 10.1097/MD.0000000000002567. (SCI A)
  24. F-18 FDG PET/CT as a Surveillance Tool for the Detection of Locoregionally Advanced Nasopharyngeal Carcinoma Recurrences in an Endemic Area. Annals of Nuclear Medicine and Molecular Imaging. 2016;29:10-22. (First author)
  25. Clinical utility of multimodality imaging with dynamic contrast-enhanced MRI, diffusion-weighted MRI, and 18F-FDG PET/CT for the prediction of neck control in oropharyngeal or hypopharyngeal squamous cell carcinoma treated with chemoradiation. PLoS One. 2014;9:e115933. (SCI A)
  26. Predictors of pathological complete response to neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma. World J Surg Oncol. 2014;12:170. DOI: 10.1186/1477-7819-12-170. (SCI A)
  27. Detection of synchronous cancers by fluorodeoxyglucose positron emission tomography/computed tomography during primary staging workup for esophageal squamous cell carcinoma in Taiwan. PLoS One. 2013;8:e82812. eCollection 2013. DOI: 10.1371/journal.pone.0082812. (SCI A)
  28. Interval Between Neoadjuvant Chemoradiotherapy and Surgery for Esophageal Squamous Cell Carcinoma: Does Delayed Surgery Impact Outcome? Ann Surg Oncol. 2013:20:4245–4251. DOI:10.1245/s10434-013-3139-7. (SCI A)
  29. Dynamic contrast-enhanced MR imaging predicts local control in oropharyngeal or hypopharyngeal squamous cell carcinoma treated with chemoradiotherapy. PLoS One. 2013:7;8:e72230. DOI:10.1371/journal.pone.0072230. (SCI A)
  30. Clinical scenario of EBV DNA follow-up in patients of treated localized nasopharyngeal carcinoma. Oral Oncol. 2013;49:620-625. DOI:10.1016/j.oraloncology.2013.02.006. (SCI A)
  31. Prognostic implications of post-therapy 18F-FDG PET in patients with locoregionally advanced nasopharyngeal carcinoma treated with chemoradiotherapy. Ann Nucl Med. 2013;27:710-719. (First author, IF=2.668)
  32. Plasma Epstein-Barr virus DNA concentration and clearance rate as novel prognostic factors for metastatic nasopharyngeal carcinoma. Head Neck. 2012;34:1064-1070. (SCI A)
  33. Misinterpretation of FDG-avid Pelvic Lymph Node Lesions as Distant Failure in a Patient with Recurrent Lung Cancer. Annals of Nuclear Medicine and Molecular Imaging. 2012;25:206-210.
  34. Pretreatment (18)F-FDG PET standardized uptake value of primary tumor and neck lymph nodes as a predictor of distant metastasis for patients with nasopharyngeal carcinoma. Oral Oncol. 2013;49:169-174. DOI:10.1016/j.oraloncology.2012.08.011. (SCI A)
  35. The role of (18)F-FDG PET/CT metabolic tumour volume in predicting survival in patients with metastatic nasopharyngeal carcinoma. Oral Oncol. 2013;49:71-78. DOI:10.1016/j.oraloncology.2012.07.016. (First author, IF=6.8)
  36. Utility of 18F-fluoride PET/CT and 18F-FDG PET/CT in the Detection of Bony Metastases in Heightened-risk Head and Neck Cancer Patients. J Nucl Med. 2012;53:1730-1735. DOI:10.2967/jnumed.112.104893. (First author, IF=10.057)
  37. Uterine cervical melanoma presenting with rapid progression detected by PET/CT. Acta Radiologica. 2012;1:16. DOI:10.1258/arsr.2012.120026. (SCI A)
  38. Prognostic Significance of 18F-FDG PET Parameters and Plasma Epstein-Barr Virus DNA Load in Patients with Nasopharyngeal Carcinoma. J Nucl Med. 2012;53:21-28. DOI: 10.2967/jnumed.111.090696. (SCI A)
  39. Clinical utility of 18F-FDG PET parameters in patients with advanced nasopharyngeal carcinoma: predictive role for different survival endpoints and impact on prognostic stratification. Nucl Med Commun. 2011;32:989-996. DOI:10.1097/MNM.0b013e3283495662. (First author, SCI A)
  40. Comparison of PET/CT and MRI for the detection of bone marrow invasion in patients with squamous cell carcinoma of the oral cavity. Oral Oncol. 2011; 47:288-295. DOI:10.1016/j.oraloncology.2011.02.010. (SCI A)
  41. 18F-FDG PET/CT and 3.0 Tesla Whole-body MRI for the Detection of Distant Metastases and Second Primary Tumors in Patients with Untreated Oropharyngeal/Hypopharyngeal Carcinoma: A Comparative Study. Eur J Nucl Med Mol Imaging. 2011;38:1607-1619. DOI:10.1007/s00259-011-1824-y. (First author, , IF=9.236)
  42. PET/CT and 3-T whole-body MRI in the detection of malignancy in treated oropharyngeal and hypopharyngeal carcinoma. Eur J Nucl Med Mol Imaging. 2011;38:996-1008. DOI: 10.1007/s00259-011-1740-1. (SCI A)
  43. Pretreatment evaluation of distant-site status in patients with nasopharyngeal carcinoma: accuracy of whole-body MRI at 3-Tesla and FDG-PET-CT. Eur Radiol. 2009;19:2965-2976. DOI: 10.1007/s00330-009-1504-5. (SCI A)
  44. Comprehensive imaging of residual/ recurrent nasopharyngeal carcinoma using whole-body MRI at 3 T compared with FDG-PET-CT. Eur Radiol. 2010; 20:2229-2240. DOI:10.1007/s00330-010-1784-9. (SCI A)
  45. 18F-FDG PET for retropharyngeal lymph node metastasis in oropharyngeal and hypopharyngeal cancers: impact on diagnosis and prediction analysis. Nucl Med Commun. 2010;31:260-265. DOI:10.1097/MNM.0b013e3283360133. (First author, SCI A)
  46. Pretreatment T3-4 Stage is an Adverse Prognostic Factor in Patients with Esophageal Squamous Cell Carcinoma Who Achieve Pathological Complete Response Following Preoperative Chemoradiotherapy. Ann Surg. 2009;249:392-396. DOI: 10.1097/SLA.0b013e3181949e9f. (SCI A)
  47. Red blood cell scintigraphy in children with acute massive gastrointestinal bleeding. Pediatrics International. 2008;50:199-203. DOI:10.1111/j.1442-200X.2008.02552.x.
  48. Salvage surgery after failed chemoradiotherapy in squamous cell carcinoma of the esophagus. Eur J Surg Oncol. 2009;35:289-294. DOI:10.1016/j.ejso.2008.02.014. (SCI A)
  49. Staging of untreated nasopharyngeal carcinoma with PET/CT: comparison with conventional imaging work-up. Eur J Nucl Med Mol Imaging. 2009;36:12-22. DOI:10.1007/s00259-008-0918-7. (SCI A)
  50. Distant metastases and synchronous second primary tumors in patients with newly diagnosed oropharyngeal and hypopharyngeal carcinomas: evaluation of (18)F-FDG PET and extended-field multi-detector row CT. Neuroradiology. 2008;50:969-79 DOI:10.1007/s00234-008-0426-2. (SCI A)
  51. Prediction for distant failure in patients with stage M0 nasopharyngeal carcinoma: The role of standardized uptake value. Oral Oncol. 2009;45:52-8. DOI:10.1016/j.oraloncology.2008.03.010. (First author)
  52. Intractable bleeding from solitary mandibular metastasis of hepatocellular carcinoma. World J Gastroenterol. 2007;13:4526-4528. (SCI A)
  53. 18F-FDG PET can replace conventional work-up in primary M staging of nonkeratinizing nasopharyngeal carcinoma. J Nucl Med. 2007;48:1614-1619. DOI:10.2967/jnumed.107.043406. (SCI A)
  54. Prospective Study of [18F]Fluorodeoxyglucose Positron Emission Tomography and Computed Tomography and Magnetic Resonance Imaging in Oral Cavity Squamous Cell Carcinoma With Palpably Negative Neck. J Clin Oncol. 2006;24:4371-4376. DOI:10.1200/JCO.2006.05.7349. (SCI A)
  55. Differential Roles of 18F-FDG PET in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma after Primary Curative Therapy: Response Evaluation and Impact on Management. J Nucl Med. 2006; 47:1447-1454. (First author, IF=10.057)
  56. Advantages and pitfalls of 18F-fluoro-2-deoxy-D-glucose Positron Emission Tomography in detecting locally residual or recurrent nasopharyngeal carcinoma: comparison with Magnetic Resonance Imaging. Eur J Nucl Med Mol Imaging. 2006;33:1032-1040.DOI:10.1007/s00259-005-0054-6. (First author, IF=9.236)
  57. (18)F-FDG-PET for evaluation of the response to concurrent chemoradiation therapy with intensity-modulated radiation technique for Stage T4 nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2006; 65:1307-1314. DOI: 10.1016/j.ijrobp.2006.02.031. (SCI A)
  58. Upper pole of a duplex kidney mimicking adrenal incidentaloma in 18F-fluoro-2-deoxy-D-glucose positron emission tomography: a pitfall in diagnosis. Br J Radiol. 2006; 79:50-52. DOI: http://dx.doi.org/10.1259/bjr/38262574. (First author, SCI A)
  59. [18F]fluorodeoxyglucose positron emission tomography is more sensitive than skeletal scintigraphy for detecting bone metastasis in endemic nasopharyngeal carcinoma at initial staging. J Clin Oncol. 2006; 24:599-604. DOI:10.1200/JCO.2005.03.8760. (SCI A)
  60. Staging of untreated squamous cell carcinoma of buccal mucosa with 18F-FDG PET: comparison with head and neck CT/MRI and histopathology. J Nucl Med. 2005;46:775-781. (SCI A)
  61. The value of 18F-FDG PET in the detection of stage M0 carcinoma of the nasopharynx. J Nucl Med. 2005;46:405-410. (SCI A)
  62. Nasopharyngeal carcinoma staging by (18)F-fluorodeoxyglucose positron emission tomography. Int J Radiat Oncol Biol Phys. 2005;62:501-507. DOI: 10.1016/j.ijrobp.2004.09.057. (SCI A)
  63. 18F-FDG PET and CT/MRI in Oral Cavity Squamous Cell Carcinoma: A Prospective Study of 124 Patients with Histologic Correlation. J Nucl Med. 2005;46:1136-1143. (SCI A)
  64. Clinical Impact of 18F-Fluorodeoxyglucose Positron Emission Tomography in Patients with Lung Cancer: Experience of Linko Chang-Gung Memorial Hospital. Ann Nucl Med Sci. 2005;18:67-77. (First author)
  65. Are dual-phase (18)F-FDG PET scans necessary in nasopharyngeal carcinoma to assess the primary tumour and loco-regional nodes? Eur J Nucl Med Mol Imaging. 2005;32:541-548.DOI:10.1007/S00259-004-1719-2. (SCI A)
  66. False-Positive Findings on F-18 Fluoro-2-deoxy-D-glucose Positron Emission Tomography in a Patient With Nasopharyngeal Carcinoma and Extensive Sinusitis. Clin Nucl Med. 2005;30:62–63. DOI:10.1200/JCO.2010.28.7052. (First author, SCI A)
  67. Clinical usefulness of 18F-FDG PET in nasopharyngeal carcinoma patients with questionable MRI findings for recurrence. J Nucl Med. 2004;45:1669-1676. (SCI A)
  68. Nodal metastases of nasopharyngeal carcinoma: patterns of disease on MRI and FDG PET. Eur J Nucl Med Mol Imaging. 2004;31:1073-1080. DOI:10.1007/S00259-004-9. (SCI A)
  69. False positive fluorine-18 fluorodeoxy-D-glucose positron emission tomography finding caused by osteoradionecrosis in a nasopharyngeal carcinoma patient. Br J Radiol. 2004;77:257-260. DOI: http://dx.doi.org/10.1259/bjr/69516821. (SCI A)
  70. Diffuse cutaneous plasmacytomas demonstrated on gallium-67 imaging. Kaohsiung J Med Sci. 2003;19:193-5.
  71. Diagnosis of Bile Peritonitis Caused by Rupture of Choledochal Cyst via 99mTc-DISIDA Cholescintigraphy: A Case Report. Ann Nucl Med Sci. 2002;15:147-151. (First author)

獎項(Award)

  • Best abstract award from Taiwan, Annual Congress of the Societyof Nuclear Medicine and Molecular Imaging, 2016 (San Diego, USA)
  • Poster award, Clinical Oncology, Annual Congress of the Societyof Nuclear Medicine and Molecular Imaging, 2016 (San Diego, USA)
  • Presentation selected for Highlight Talking, Annual Congress of the Societyof Nuclear Medicine and Molecular Imaging, 2016 (San Diego, USA)

 

Copyright © 2017 花蓮慈濟醫院. 版權所有. 地址：花蓮市中央路三段707號　連絡電話：03-8561825